B12 And Verbal Recall — The Connection Most People Miss
Quick Read Struggling to find a word or remember someone’s name may feel like normal ageing, but research suggests it’s
Subscribe to the distribution list, to get regular updates on supplement research for health,
🧠 NeuroBright Our evidence-based brain supplement formulated from 1.7M research papers
Lion’s mane mushroom contains compounds that stimulate nerve growth factor, a protein your brain uses to keep nerve cells healthy and connected. Research shows this pathway starts deteriorating years before Alzheimer’s symptoms appear, making it a potential target for prevention. Laboratory and animal studies demonstrate that lion’s mane compounds reduce inflammation, protect against oxidative stress, and promote nerve cell growth and connectivity through multiple mechanisms.
However, human clinical trial evidence remains limited. While the biological mechanism is credible and well-understood, we don’t yet have proof that lion’s mane supplementation meaningfully prevents or slows cognitive decline in humans over time. One animal study found it reduced anxiety but didn’t improve memory. Supplement quality varies widely, and optimal human doses haven’t been established.
Lion’s mane has centuries of use as food with no known toxicity concerns at reasonable doses. For people in their 40s and 50s concerned about brain health, the downside risk appears minimal while the potential upside could be significant, especially when combined with exercise, sleep, and a healthy diet. Choose supplements that specify whether they contain fruiting body or mycelium, as these have different active compounds.
Verdict: Lion’s mane has a solid mechanistic foundation and a good safety profile, but human evidence for Alzheimer’s prevention is still too early to call it proven, so think of it as a potentially helpful addition to brain-healthy habits rather than a standalone solution.
What if the most promising clue in Alzheimer’s research wasn’t a pharmaceutical compound developed in a lab, but a shaggy white mushroom that’s been eaten across East Asia for centuries? And what if the reason it might matter isn’t some vague notion of “superfoods”, but a very specific, well-understood biological pathway that starts breaking down in your brain *years* before any memory symptoms appear?
That’s the genuinely intriguing story behind lion’s mane (*Hericium erinaceus*) and its relationship with nerve growth factor, or NGF. It’s not a miracle cure story. The human evidence is still thin. But the mechanism is real, the early science is serious, and if you care about your brain in your 40s, 50s and 60s, this is worth understanding properly.
Vitacuity analysed over 1.77 million research papers and selected the most relevant studies on this topic. Here’s what the evidence actually shows, and where it runs out.
To understand why lion’s mane is interesting, you first need to understand NGF, and why losing it is such bad news.
Nerve growth factor is a protein your brain produces to keep neurons alive, healthy and well-connected. Think of it as a kind of biological maintenance crew for your nervous system, it promotes the growth, survival and organisation of neurons, and it’s particularly critical for the *cholinergic system*, the network of brain cells that use acetylcholine as their signalling chemical [4].
Why does that matter? Because the loss of cholinergic function is one of the defining features of Alzheimer’s disease. When these neurons deteriorate, memory and cognition deteriorate with them.
Here’s the alarming part: NGF doesn’t simply switch off when Alzheimer’s strikes. Research published in 2025 describes what scientists call *NGF dysmetabolism*, a gradual disruption of the normal NGF pathway that begins *years before* mild cognitive impairment develops [4]. It’s a slow unravelling, not a sudden collapse.
What goes wrong? The balance between two key receptors shifts in a dangerous direction. NGF normally binds to TrkA receptors, which have neuroprotective effects. But as the brain ages and NGF dysmetabolism progresses, the ratio tips towards p75NTR receptors, which are stimulated by proNGF, the precursor form of NGF, and this has actively *harmful* effects on neurons [4]. The system essentially starts working against itself.
This is precisely where lion’s mane enters the picture. Its two key bioactive compound groups, *hericenones* (found in the fruiting body) and *erinacines* (found in the mycelium), have been shown in laboratory and animal studies to stimulate NGF synthesis and support the kind of neuronal maintenance that this pathway is supposed to provide [3][14].
Evidence grade: Early stage, laboratory studies using human cell lines, animal confirmation. Human trials needed.
One of the foundational pieces of research on this topic was published back in 2008. Scientists tested extracts from four edible mushrooms on 1321N1 human astrocytoma cells (a type of human brain cell line used in research). Of the four mushrooms tested, only *Hericium erinaceus* promoted NGF gene expression, and it did so in a concentration-dependent way, meaning the more extract was applied, the stronger the effect [8].
The same study found that the conditioned medium from these NGF-stimulated cells then *promoted neurite outgrowth* in PC12 cells, essentially, it encouraged nerve cells to grow the projections they need to communicate with other neurons [8]. The researchers identified that the mechanism works through activation of the JNK signalling pathway, which then increases NGF gene expression [8].
Interestingly, isolated hericenones C, D and E *on their own* did not replicate this effect, suggesting that the full mushroom extract contains other active compounds that work in combination, or that the mechanism is more complex than a single molecule [8].
This was confirmed *in vivo* in the same study: mice fed a diet containing 5% dried *H. erinaceus* powder for 7 days showed increased NGF mRNA expression in the hippocampus, the brain region most associated with memory formation [8].
Evidence grade: Early stage, isolated compound studies in cell lines. Human data not yet available.
A 2021 study isolated four specific isoindolinone compounds from the fruiting bodies of *Hericium erinaceus*, including one, isohericerinol A, that was newly identified in nature [13]. Researchers tested their neurotrophic effects in C6 glioma cells and N2a neuronal cells.
Isohericerinol A produced the strongest increase in NGF production, followed by corallocin A and hericerin [13]. Critically, the increased NGF then promoted *neurite outgrowth* in the neuronal cells, again, that all-important step of neurons growing the connections they need to function properly.
What’s particularly notable: Western blot analysis showed these compounds also increased protein expression of *brain-derived neurotrophic factor (BDNF)* and *synaptophysin*, a marker of synaptic density and connectivity [13]. This matters because synaptophysin levels are directly associated with cognitive function, and synaptic loss is a key feature of Alzheimer’s pathology.
To be clear: this is laboratory work, not human trial data. But the specificity of the findings, identifying discrete molecules and tracking their downstream effects at a protein level, represents exactly the kind of mechanistic groundwork that credible drug development is built on.
Evidence grade: Promising, strong mechanistic data from lab and animal studies, with some early human evidence emerging. Larger human trials needed.
The erinacines, the bioactive compounds found primarily in the mycelium of *H. erinaceus*, have attracted significant research attention for their neuroprotective properties. A 2025 review specifically focused on unveiling their role describes multiple mechanisms through which erinacines may act against neurodegeneration [3][14].
These include stimulating NGF synthesis, reducing neuroinflammation, and potentially acting against the beta-amyloid plaques and tau tangles that are the hallmarks of Alzheimer’s pathology [3][14]. A separate 2013 study demonstrated that aqueous extract of *H. erinaceus* promoted neurite outgrowth in NG108-15 neuroblastoma-glioma cells, with the combination of 10 ng/mL NGF and just 1 μg/mL of mushroom extract producing a 60.6% increase in neurite outgrowth, a synergistic effect suggesting that lion’s mane may amplify the brain’s own NGF activity rather than simply replacing it [9].
Importantly, a 2025 narrative review examining *H. erinaceus* specifically in the context of Alzheimer’s disease notes that current Alzheimer’s medications address only symptoms and demonstrate limited efficacy, partly due to biological barriers (such as the blood-brain barrier). The small molecular size of erinacines is considered a potential advantage here, as they may cross the blood-brain barrier more effectively than larger pharmaceutical compounds [1][6].
Evidence grade: Early stage to Promising, laboratory and animal evidence is consistent; human trial data limited.
Oxidative stress and neuroinflammation are not just bystanders in Alzheimer’s disease, they actively accelerate neuronal damage. A 2019 study examined both hot water and ethanolic extracts of *H. erinaceus* fruiting bodies and found evidence of neuroprotective activity through anti-inflammatory and antioxidant mechanisms in neuron-glia cell systems [12].
This adds an important second dimension to the lion’s mane story. It’s not *only* about the NGF pathway. The mushroom appears to work across multiple mechanisms simultaneously, reducing the inflammatory environment that damages neurons, while also stimulating the growth factors that support their survival and connectivity [12][15].
A 2021 broader review of medicinal mushrooms and neurodegenerative diseases confirmed this multi-pathway picture for *H. erinaceus* specifically, noting mechanisms including reduction of oxidative stress, modulation of acetylcholinesterase activity (the enzyme that breaks down acetylcholine), and regulation of neurotrophin synthesis [15].
Evidence grade: Promising for anxiety-related effects in animal models. Spatial memory effects remain unproven.
A 2022 study used mice specifically modelling Alzheimer’s disease through tau pathology, one of the two major pathological hallmarks of the disease, to assess the effects of *H. erinaceus* supplementation over 4.5 months [10]. This is notable because most previous animal research had used different AD models or healthy mice.
The results were mixed, and the researchers were refreshingly honest about this. Tau mice fed lion’s mane showed significantly shorter latencies to enter the centre of an open field (p < 0.05) and spent significantly more time in the open arms of an elevated zero maze (p < 0.001) compared to tau control mice, indicating real anxiolytic (anxiety-reducing) effects [10].
However, and this is important, *no improvements were seen in spatial memory or activities of daily living* [10]. The authors concluded that *H. erinaceus* may have genuine therapeutic value for anxiety symptoms in Alzheimer’s disease, but that its effects on cognitive decline in tau-specific models remain unproven [10].
A separate 2022 review covering both preclinical and clinical evidence on *H. erinaceus* and memory in Alzheimer’s disease noted that while preclinical data is encouraging, clinical evidence remains limited and more robust human trials are needed [11].
This is the part where we have to be genuinely honest with you, and it matters.
The human trial evidence is sparse. Almost all of the mechanistic and outcome data described above comes from cell cultures, animal models, and laboratory studies. While these are important and the mechanisms identified are scientifically credible, they don’t automatically translate to meaningful effects in humans. The biology of a living human brain over decades is vastly more complex than a mouse model over 4.5 months.
We don’t have dose-response data in humans. We know erinacines and hericenones are the key active compounds, and we know that the mycelium (erinacines) and fruiting body (hericenones) contain different compounds with somewhat different mechanisms. But the optimal dose for human cognitive benefit has not been established through rigorous clinical trials [1][6].
Fruiting body vs. mycelium matters, and is often ignored on supplement labels. The 2025 erinacine review specifically focuses on mycelial compounds [3][14], while other studies have used fruiting body extracts [8][9][12]. These are genuinely different preparations. A supplement that doesn’t specify which part of the mushroom was used, and at what concentration, is difficult to evaluate against the published research.
The NGF pathway findings are largely still in animals and cell lines. The 2025 NGF dysmetabolism review [4] is compelling and clearly articulates *why* this pathway matters for Alzheimer’s, but confirming that lion’s mane supplementation meaningfully restores or supports this pathway in living humans, over years, remains to be demonstrated.
Anxiolytic effects may be more established than cognitive effects. The 2022 tau mouse study found real anxiety-reducing effects but no memory improvement [10]. It’s possible that lion’s mane is genuinely helpful for neurological anxiety (which is common in early Alzheimer’s) but less directly impactful on cognitive decline than its NGF-stimulating mechanism might suggest.
We don’t have long-term safety data from human trials. The available evidence suggests *H. erinaceus* is well-tolerated and non-cytotoxic at studied doses [9], and it has centuries of use as a food in Asian cuisine. But formal long-term human safety studies are limited.
Here’s how a sensible, well-informed person should think about this.
The lion’s mane story is genuinely interesting, not as hype, but as credible early-stage science built on a well-understood biological mechanism. NGF dysmetabolism is a real, measurable phenomenon that precedes Alzheimer’s symptoms by years [4]. The compounds in lion’s mane, particularly erinacines in the mycelium, have been shown in laboratory and animal studies to stimulate NGF synthesis, promote neuronal growth and connectivity, reduce neuroinflammation, and reduce oxidative stress [3][8][9][12][13][14]. That’s a coherent, multi-layered mechanistic case.
What it is *not* is a proven Alzheimer’s prevention therapy in humans. The clinical trial evidence is still thin, and we need to say that clearly.
So what would a practical, intelligent person in their 40s or 50s actually do with this?
1. Don’t wait for perfect evidence if the risk profile is low. Lion’s mane has been consumed as food for centuries, shows no toxicity concerns at reasonable doses in available research, and costs very little per day. The downside risk is minimal. The potential upside, if even a fraction of the mechanistic evidence translates, is significant.
2. Choose your supplement carefully. Look for products that specify whether they use fruiting body, mycelium, or a dual extract, and that provide a meaningful dose of the actual bioactive compounds (erinacines and/or hericenones), not just powdered mushroom biomass. This is where most of the supplement market falls short.
3. Think of it as part of a system, not a standalone solution. The research suggests lion’s mane works through the same pathways, NGF support, inflammation reduction, oxidative stress management, that good sleep, regular exercise, and a diet rich in antioxidants also support. It’s additive, not a replacement for those foundations.
4. Start now rather than later. The NGF dysmetabolism research is clear that this pathway begins deteriorating *years before symptoms appear* [4]. If there’s a window of opportunity for prevention, it opens well before any diagnosis. Your 50s are not too early to take this seriously.
5. Watch this space. This is an area of active research in 2025. The mechanistic foundations are solid enough that clinical trials are a logical next step, and results over the next few years may significantly change what we can say with confidence.
The honest summary: lion’s mane is not a miracle. But it’s one of the more scientifically grounded natural interventions for brain health that exists today, with a plausible mechanism, a safe profile, and enough early-stage evidence to make it worth considering seriously. Just go in with realistic expectations and a good-quality product.
[1] Hericium erinaceus: A possible future therapeutic treatment for the prevention and delayed progression of Alzheimer’s disease?, A narrative review (2025). DOI: 10.1017/S0954422425000058 | https://pubmed.ncbi.nlm.nih.gov/39988819/
[2] Research hypothesis: Psilocybe cubensis and Hericium erinaceus as novel approaches for mitigating neurological symptoms of Alzheimer’s disease (2025). DOI: 10.1002/alz70856_097076 | https://pubmed.ncbi.nlm.nih.gov/41442078/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12731483/
[3] Unveiling the role of erinacines in the neuroprotective effects of Hericium erinaceus (2025). DOI: 10.3389/fphar.2025.1582081 | https://pubmed.ncbi.nlm.nih.gov/40626304/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230622/
[4] Dysmetabolism of the nerve growth factor pathway in the aging brain plays a pivotal role in cognitive decline (2025). DOI: 10.2460/javma.25.09.0578 | https://pubmed.ncbi.nlm.nih.gov/41349274/
[5] Mushrooms: Potential Agents for the Prevention and Slowdown of Alzheimer’s Disease: A Review (2025). https://pubmed.ncbi.nlm.nih.gov/40749181/
[6] Hericium erinaceus: A possible future therapeutic treatment for the prevention and delayed progression of Alzheimer’s disease?, A narrative review (2025) [second database entry]. DOI: 10.1017/S0954422425000058 | https://pubmed.ncbi.nlm.nih.gov/39988819/
[8] Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells (2008). https://pubmed.ncbi.nlm.nih.gov/18758067/
[9] Neurotrophic properties of the Lion’s mane medicinal mushroom, Hericium erinaceus (Higher Basidiomycetes) from Malaysia (2013). https://pubmed.ncbi.nlm.nih.gov/24266378/
[10] Lion’s Mane (Hericium erinaceus) and cognitive and behavioural effects in tau-pathology Alzheimer’s model mice (2022). DOI: 10.3390/bs12070235 | https://pubmed.ncbi.nlm.nih.gov/35877305/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312024/
[11] The Monkey Head Mushroom and Memory Enhancement in Alzheimer’s Disease (2022). DOI: 10.3390/cells11152284 | https://pubmed.ncbi.nlm.nih.gov/35892581/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331832/
[12] Lion’s Mane Mushroom, Hericium erinaceus, neuroprotective, anti-inflammatory and antioxidant effects (2019). DOI: 10.3390/antiox8080261 | https://pubmed.ncbi.nlm.nih.gov/31374912/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720269/
[13] Neurotrophic isoindolinones from the fruiting bodies of Hericium erinaceus (2021). DOI: 10.1016/j.bmcl.2020.127714 | https://pubmed.ncbi.nlm.nih.gov/33246107/
[14] Unveiling the role of erinacines in the neuroprotective effects of Hericium erinaceus (2025) [second database entry]. DOI: 10.3389/fphar.2025.1582081 | https://pubmed.ncbi.nlm.nih.gov/40626304/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230622/
[15] Therapeutic applications of mushrooms and their biomolecules along with a glimpse of in silico approach in neurodegenerative diseases (2021). DOI: 10.1016/j.biopha.2021.111377 | https://pubmed.ncbi.nlm.nih.gov/33601145/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Struggling to find a word or remember someone’s name may feel like normal ageing, but research suggests it’s
Quick Read Chronic loneliness, the subjective feeling that your relationships don’t match what you need, physically damages your brain. Research
Free guide: The research behind brain health supplements
Plus our weekly research digest — straight to your inbox.
Just leave your email address.